The non–vitamin K antagonist oral anticoagulants (NOACs), such as the thrombin inhibitor
(dabigatran) and the direct factor Xa inhibitors (rivaroxaban, apixaban, and edoxaban), have …

Abstract Introduction Novel oral anticoagulants (NOACs) expanded the options for stroke
prevention in atrial fibrillation (AF). Earlier studies comparing their relative effectiveness and …

Aims Contemporary data regarding atrial fibrillation (AF) management and current use of
oral anticoagulants (OACs) for stroke prevention are needed. Methods and results The …

Background and aim Current observational studies have compared the effectiveness and
safety of edoxaban with other oral anticoagulants in patients with AF, but the results are still …

Background Oral anticoagulants are prescribed in non-valvular atrial fibrillation for stroke
prevention; however, little is known about the current management of anticoagulation in …

Purpose The purpose of this study was to investigate the influence of patient characteristics
such as age and stroke and bleeding risks on decisions for antithrombotic treatment in …

Purpose: To systematically review available evidence of indirect comparisons from RCTs
and direct comparisons from observational studies regarding the comparative effectiveness …

Balancing stroke prevention and risk of bleeding in patients with atrial fibrillation (AF) is
challenging. Direct oral anticoagulants (DOACs) are by now considered standard of care for …

Oral vitamin K antagonists (VKAs), warfarin, have been in routine clinical use for almost 70
years for various cardiovascular conditions. Direct-Acting Oral Anticoagulants (DOACs) have …

Aims Non-vitamin K antagonist oral anticoagulants (NOACs) are effective and safe
alternatives compared with vitamin K antagonists (VKAs) for thromboembolic prevention in …